Sentences with phrase «with study drugs»

The main purpose of this study is to find out more about the side effects of the study drug, MM - 121, when combined with the study drugs, docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM - 121 with docetaxel or pemetrexed.

If your teen is desperate to achieve more, at all costs, he may be at an increased risk to experiment with study drugs.

Safety was generally similar between inclisiran and placebo apart from a small numerical excess of injection site reactions with the study drug.

Overall, 351 patients (77 percent) completed treatment with the study drug with valid 12 - week N - terminal pro-B-type natriuretic peptide (NT - proBNP) levels and no major protocol deviation.

Dr. Ready said the trial was not powered to show overall survival differences, and thus the slight improvement with the study drug should be interpreted with caution.

There were more serious adverse events with the study drug compared to placebo, with 4.7 % of pemetrexed patients experiencing grade 3 or 4 fatigue and 6.4 % suffering grade 3 or 4 anemia.

The main purpose of this study is to assess how metastatic or surgically unresectable urothelial carcinoma with FGF / FGFR alterations responds to treatment with the study drug, INCB054828.

Not exact matches

A small 2006 study found ginkgo was as effective as the drug donepezil for boosting attention and memory in people with mild to moderate Alzheimer's.

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

After that, Watson will take assist by providing both physician and patient with a report that includes the most relevant drug trial and academic studies for their specific conditions.

Swiss drug giant Novartis is partnering with California - based Science 37 in an effort to expand clinical study participation (while lowering the costs of such studies) through «virtual» trials.

Bristol - Myers emphasized Opdivo's other successes and ongoing studies evaluating its effectiveness in combination with the company's other cancer drugs.

The company is chasing an at least $ 80 million IPO to help fund the phase 3 studies that would be necessary for the Food and Drug Administration (FDA) to clear the treatment (the company has made modifications to the experimental, once - a-day pill that fights brain plaque buildup associated with Alzheimer's).

Pagan said that a larger, more comprehensive study must be done before determining the drug's true impact, but if the drug's effectiveness is confirmed in such tests, nilotinib could become the first treatment to impede the killing of brain cells that's consistent with Parkinson's, according to NPR.

However, Spicer then signaled that the White House sees recreational pot very differently, with the press secretary even attempting to link recreational use of the drug to the abuse of opioid drugs across the U.S. (In fact, there has been little scientific evidence linking marijuana legalization to opioid use, with some studies actually showing a decrease in opioid overdoses in states where legal marijuana is available.)

Through week 48, Biktarvy was found to be statistically non-inferior to ABC / DTG / 3TC with a numerically lower incidence of mild or moderate study drug - related adverse events and no treatment - emergent resistance;

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

The project is to take place under the auspices of the Center for Supply Chain Studies, with the goal of bringing pharmaceutical firms into compliance with the Drug Supply Chain Security Act, passed in 2013.

Another migraine drug, lasmiditan, which Lilly picked up with its 2017 acquisition of Colucid Pharmaceuticals, is in late - stage clinical studies.

The startup describes itself as a deep data platform for the study of exosomes, which are small lipid vesicles — air - or fluid - filled cavities — that are excreted from cells and which deliver information that Mantra plans to use to come up with new drug therapies.

Credit Suisse analysts said patisiran's data seemed to have «solid safety» compared with Ionis Pharmaceuticals Inc's rival drug, which cleared a key study but raised safety concerns.

Alkermes is partnering with Biogen on ALKS 8700, a drug for multiple sclerosis that improves on Biogen's $ 4 billion Tecfidera, and a tolerability study should read out in the first half of 2018, with submission to the FDA expected in the the second half.

Rick Perry and Michele Bachmann, two presidential candidates who sparred over the issue of Texas vaccinations, may be floundering in the polls, but the topic of Merck's controversial Gardasil is heating up — with an Austrian physician who studied the drug saying it is not only dangerous, but useless in reducing cervical cancer, the stated reason it was administered to young girls at the behest of Gov. Perry.

Celgene will help fund a study with BeiGene's lung cancer hopeful, tislelizumab, and in return pay BeiGene royalties on any U.S. sales of the drug.

I have a bachelor degree in social studies and worked for many years with people at group homes in Denmark and experienced everyday how focused the doctors were on trying to cure the patients with drugs.

As recently as February researchers with the US Food and Drug Administration ran a study that mimicked the small doses of BPA that people may come into contact with.

Carrageenan is such an efficient inflammatory agent and carcinogen, it is widely used with laboratory animals to study the molecular signals involved in cancer and anti-inflammatory drugs.

While the Food and Drug Administration (FDA) did not require approval of cryotherapy because it is a non-invasive procedure, the company believes that additional studies can help business with the added confirmation and explanation of benefits, as well as increase exposure of cryotherapy to the mainstream.

In this study, and in opposition to findings elsewhere, higher levels of social support were associated with greater depressive symptomatology, leading researchers to speculate that for low - income men the perceived costs of reciprocity may have deterred them from utilizing available support; or that peer groups may have influenced their alcohol or drug use, or placed demands on their resources (Anderson et al, 2005).

Students would buy the attention - deficit drugs from other students with an ADHD diagnosis before AP Exams, research papers or SAT / ACT tests, in hope of increased concentration and a greater ability to stay awake during studying.

To overcome the drowsiness caused by sleep deprivation, many kids resort to taking «study drugs» like Adderall (meant for kids with ADHD), which can impair long - term learning and can produce fatal arrhythmias.

For example, in one study with paroxetine (Paxil), the baby got less than 0.3 % of the drug for each kilogram of his weight than the mother did (the mother got over 300 micrograms per kg per day, whereas the baby got about 1 microgram per kg per day).

scientific study has learneed that the benzodiazepine drug treatments, the actual Valiums along with Xanaxes, perform how they do by interesting any natural chemical called «gamma - aminobutyric acid, or even Gamma aminobutyric acid, therefore selling a relaxing impact in only exactly the same as the highly habit forming opioids.

The latter research findings form the basis for patents and clinical studies with the aim to create a pharmaceutical drug for relief of menopausal symptoms.

ACEs usually refers to the 10 types of childhood adversity that were measured in the U.S. Centers for Disease Control and Prevention's Adverse Childhood Experiences (ACE) Study: physical abuse, emotional abuse, sexual abuse, physical neglect, emotional neglect, a family member who's an alcoholic or addicted to other drugs, a family member diagnosed with a mental illness, witnessing a mother being abused, a family member in prison, and loss of a parent through separation or divorce.

And a large 2013 study found that breastfeeding babies younger than 3 months who bed - shared with adults were five times more likely to die of SIDS, even when their parents were not using tobacco, alcohol, or drugs.

Sugar addiction is a specific type of food addiction and has been shown to develop in animal studies and to have similarities with certain kinds of drug addiction.

Many studies have shown that weed is often laced with other drugs.

Other studies have shown that children with involved fathers are less likely to do drugs or drink alcohol, will be more emotionally secure, and have better social interaction with their peers.

As with neurobehavior, effects on breastfeeding are poorly studied, and more recent randomized controlled trials comparing exposure to epidural and opiate drugs are especially misleading because opiates have a well - recognized negative effect on early breastfeeding behavior and success.103 — 107

There are few studies of the condition of epidural babies at birth, and almost all of these compare babies born after epidurals with babies born after exposure to opiate drugs, which are known to cause drowsiness and difficulty with breathing.

For the purposes of this economic evaluation, the forms were initially used in a related study funded by the National Institute of Health Research (NIHR) research for patient benefit programme «assessing the impact of a new birth centre on choice and outcome of maternity care in an inner city area,» which will be reported in full elsewhere, comparing the costs of care in a free standing midwifery unit with care in an obstetric unit in the same trust.16 The data collected included details of staffing levels, treatments, surgeries, diagnostic imaging tests, scans, drugs, and other resource inputs associated with each stage of the pathway through intrapartum and after birth care.

less than or equal to lamivudine Acquired Immune Deficiency Syndrome Antiretroviral therapy, usually means 1 - 2 drugs, used in early studies Antiretroviral zidovudine (also known as ZDV) Breastfeeding Baby Friendly Hospital Initiative Breastfeeding and HIV International Transmission Study Combined antiretroviral therapy Centers for Disease Control and Prevention Deoxyribonucleic Acid Exclusive Breastfeeding Enzyme Linked Immunosorbent Assay Food and Agrigulture Organization Fixed dose combination ART, e.g., lamividine, stavudine, and nevirapine Highly Active Antiretroviral Therapy, 3 or more drugs for more effective treatment used in later studies Human Immunodeficiency virus International Atomic Energy Agency Infant feeding Infant and young child feeding Lopinavir cubic millimetre Mother - to - Child Transmission of HIV Non-governmental organization Nevirapine Polymerase Chain Reaction People Living with HIV Prevention of Mother - to - Child Transmission Replacement Feeding Ritonavir Ribonucleic acid, one of the three major macromolecules (along with DNA and proteins) that are essential for all known forms of life single dose NVP United Nations Agencies Joint United Nations Programme on HIV / AIDS United Nations Population Fund United Nations Commissioner for Refugees United Nations Children's Fund U.S. Agency for International Development World Alliance for Breastfeeding Action United Nations World Food Programme World Health Assembly WHO 2010 Guidelines on HIV and infant feeding World Health Organization Zidovudine (same drug as AZT)

The purpose of this study was to examine weight gain in infants who are breastfed by mothers who take fluoxetine during pregnancy and after birth, compared with infants breastfed by mothers who have taken the drug sometime during pregnancy but not during the breastfeeding period.

(2) The most recent study on bedsharing and SIDS in the UK found that babies who died while sleeping with a parent were doing so in a hazardous environment, particularly on a sofa, or with a parent who had consumed alcohol or drugs.

She also instinctively bends her legs completing the protective space around the baby, making it impossible for another person to roll onto the baby without first coming into contact with her legs.15, 16 A breastfeeding mother who co-sleeps with her baby (and has not consumed alcohol, illegal or sleep - inducing drugs or extreme fatigue) also tends to be highly responsive to her baby's needs.17, 18 Studies show more frequent arousals in both mothers and babies when they co-sleep, and some researchers have suggested that this may be protective against sudden unexpected infant deaths.19 — 21 Babies are checked by their mother and breastfeed more frequently when co-sleeping than when room - sharing.22, 23

«The problem with routine prescription of prenatal Rhogam is that many babies who are Rh negative like their mothers will be exposed to the drug, and there has been no systematic study of the long - term effects of this product in babies.

In follow - up studies these youngsters tended to grow up to be teenagers with lower SAT scores, higher body mass indexes and higher rates of drug abuse.